On October 30, the FDA announced that all doses of Novo Nordisks Ozempic and Wegovy medications are now available in the U.S
In addition, intensive research focused on biological targets which could stimulate GLP-1 release in the gut or pancreas, including GPR120, SSTR5, GPR40, TGR-5 and GPR119
Recently, Pfizer also successfully secured the ownership of GLP-1 biotechnology company Metsera after a surprise bidding conflict, adding Metseras injectable asset, MET-097i (which is in Phase 2b testing and has the potential for once-a-month dosing), to its portfolio
Starting semaglutide during an active IBS flare is typically not recommended, as both the underlying condition and medication side effects can overlap and worsen symptoms
These medications are powerful metabolic agents
Compounds that demonstrate clear efficacy in rat tendon healing studies have repeatedly failed to reproduce those effects in human clinical trials this is a documented pattern across pharmaceutical development, not a theoretical concern